Case Report: Trastuzumab deruxtecan plus toripalimab in ERBB2-amplified cervical mucosal melanoma

Cervical mucosal melanoma is a rare, aggressive malignancy with poor prognosis due to delayed diagnosis and limited treatment efficacy. Current therapies, including immune checkpoint inhibitors (e.g., anti-PD-1 agents), chemotherapy, and targeted therapies, yield suboptimal response rates (<30%)...

Cijeli opis

Bibliografski detalji

Glavni autori:	Xiao-Xia Wang, Min-Xin Wang, Chao Sui
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2025-09-01
Serija:	Frontiers in Oncology
Teme:	cervical mucosal melanoma trastuzumab deruxtecan (T-DXd) genomic profiling toripalimab HER2-positive tumors
Online pristup:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1625521/full
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!